Literature DB >> 27068226

The Role of TNF Superfamily Member 13 in the Progression of IgA Nephropathy.

Seung Seok Han1,2, Seung Hee Yang2, Murim Choi3, Hang-Rae Kim3,4, Kwangsoo Kim5, Sangmoon Lee3, Kyung Chul Moon6, Joo Young Kim2, Hajeong Lee1,2, Jung Pyo Lee1,2,7, Ji Yong Jung8, Sejoong Kim1, Kwon Wook Joo1,2, Chun Soo Lim1,2,6, Shin-Wook Kang9, Yon Su Kim1,2, Dong Ki Kim10,2.   

Abstract

TNF superfamily member 13 (TNFSF13) has been identified as a susceptibility gene for IgA nephropathy in recent genetic studies. However, the role of TNFSF13 in the progression of IgA nephropathy remains unresolved. We evaluated two genetic polymorphisms (rs11552708 and rs3803800) and plasma levels of TNFSF13 in 637 patients with IgA nephropathy, and determined the risk of ESRD according to theses variable. Neither of the examined genetic polymorphisms associated with a clinical outcome of IgA nephropathy. However, high plasma levels of TNFSF13 increased the risk of ESRD. To explore the causal relationship and underlying mechanism, we treated B cells from patients (n=21) with or without recombinant human TNFSF13 (rhTNFSF13) and measured the expression of IgA and galactose-deficient IgA (GdIgA) using ELISA and flow cytometry. Treatment with rhTNFSF13 significantly increased the total IgA level among B cells, and TNFSF13 receptor blockade abrogated this increase. Furthermore, the absolute levels of GdIgA increased with rhTNFSF13 treatment, but the total IgA-normalized levels did not change. Both RNA sequencing and quantitative PCR results showed that rhTNFSF13 did not alter the expression of glycosyltransferase enzymes. These results suggest that high plasma TNFSF13 levels associate with a worse prognosis of IgA nephropathy through the relative increase in GdIgA levels.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  IgA nephropathy; glomerulonephritis; lymphocytes; outcomes

Mesh:

Substances:

Year:  2016        PMID: 27068226      PMCID: PMC5084881          DOI: 10.1681/ASN.2015060677

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  33 in total

1.  Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.

Authors:  A C Schoolwerth; D A Sica; B J Ballermann; C S Wilcox
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

Review 2.  BAFF AND APRIL: a tutorial on B cell survival.

Authors:  Fabienne Mackay; Pascal Schneider; Paul Rennert; Jeffrey Browning
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 3.  Matrix metalloproteinases as modulators of inflammation and innate immunity.

Authors:  William C Parks; Carole L Wilson; Yolanda S López-Boado
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

Review 4.  Corticosteroid therapy in IgA nephropathy.

Authors:  Jicheng Lv; Damin Xu; Vlado Perkovic; Xinxin Ma; David W Johnson; Mark Woodward; Adeera Levin; Hong Zhang; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 10.121

5.  Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

Authors:  Ludwig Kappos; Hans-Peter Hartung; Mark S Freedman; Alexey Boyko; Ernst Wilhelm Radü; Daniel D Mikol; Marc Lamarine; Yann Hyvert; Ulrich Freudensprung; Thomas Plitz; Johan van Beek
Journal:  Lancet Neurol       Date:  2014-03-06       Impact factor: 44.182

Review 6.  The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Authors:  Giuseppe Remuzzi; Norberto Perico; Manuel Macia; Piero Ruggenenti
Journal:  Kidney Int Suppl       Date:  2005-12       Impact factor: 10.545

7.  Tonsillectomy for IgA nephropathy: a meta-analysis.

Authors:  Lin-lin Liu; Li-ning Wang; Yi Jiang; Li Yao; Li-ping Dong; Zi-long Li; Xiao-li Li
Journal:  Am J Kidney Dis       Date:  2014-10-22       Impact factor: 8.860

8.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

9.  Remission of proteinuria improves prognosis in IgA nephropathy.

Authors:  Heather N Reich; Stéphan Troyanov; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2007-10-31       Impact factor: 10.121

10.  IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.

Authors:  Rosanna Coppo; Licia Peruzzi; Alessandro Amore; Antonio Piccoli; Pierre Cochat; Rosario Stone; Martin Kirschstein; Tommy Linné
Journal:  J Am Soc Nephrol       Date:  2007-05-18       Impact factor: 10.121

View more
  12 in total

1.  Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy.

Authors:  Masahiro Muto; Benoit Manfroi; Hitoshi Suzuki; Kensuke Joh; Masaaki Nagai; Sachiko Wakai; Christian Righini; Masayuki Maiguma; Shozo Izui; Yasuhiko Tomino; Bertrand Huard; Yusuke Suzuki
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

Review 2.  The Phenotypic Difference of IgA Nephropathy and its Race/Gender-dependent Molecular Mechanisms.

Authors:  Yusuke Suzuki; Renato C Monteiro; Rosanna Coppo; Hitoshi Suzuki
Journal:  Kidney360       Date:  2021-05-28

Review 3.  Is IgA nephropathy the same disease in different parts of the world?

Authors:  Hong Zhang; Jonathan Barratt
Journal:  Semin Immunopathol       Date:  2021-08-20       Impact factor: 9.623

4.  IgA Nephropathy Susceptibility Loci and Disease Progression.

Authors:  Manman Shi; Yan Ouyang; Mingxin Yang; Meng Yang; Xiaoyan Zhang; Wei Huang; Weiming Wang; Zhaohui Wang; Wen Zhang; Xiaonong Chen; Xiaoxia Pan; Hong Ren; Nan Chen; Jingyuan Xie
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-24       Impact factor: 8.237

5.  BAFF and APRIL expression as an autoimmune signature of membranous nephropathy.

Authors:  Seung Seok Han; Seung Hee Yang; Hyung Ah Jo; Yun Jung Oh; Minkyoung Park; Joo Young Kim; Hajeong Lee; Jung Pyo Lee; Sang-Ho Lee; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Dong Ki Kim
Journal:  Oncotarget       Date:  2017-12-14

6.  Association between VDR gene FokI polymorphism and renal function in patients with IgA nephropathy.

Authors:  Man-Qiu Mo; Ling Pan; Lin Tan; Ling Jiang; Yong-Qing Pan; Fu-Ji Li; Zhen-Hua Yang; Yun-Hua Liao
Journal:  PeerJ       Date:  2019-06-10       Impact factor: 2.984

Review 7.  Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem.

Authors:  Barbara Infante; Michele Rossini; Serena Leo; Dario Troise; Giuseppe Stefano Netti; Elena Ranieri; Loreto Gesualdo; Giuseppe Castellano; Giovanni Stallone
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

8.  TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.

Authors:  Yuko Makita; Hitoshi Suzuki; Toshiki Kano; Akiko Takahata; Bruce A Julian; Jan Novak; Yusuke Suzuki
Journal:  Kidney Int       Date:  2019-09-05       Impact factor: 10.612

9.  The association of tumor necrosis factor superfamily 13 with recurrence of immunoglobulin A nephropathy in living related kidney transplantation.

Authors:  Hyung Ah Jo; Seung Seok Han; Sunhwa Lee; Joo Young Kim; Seung Hee Yang; Hajeong Lee; Jae Seok Yang; Jung Pyo Lee; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Curie Ahn; Jin Suk Han; Dong Ki Kim
Journal:  BMC Nephrol       Date:  2019-01-31       Impact factor: 2.388

10.  Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.

Authors:  Giuseppe Stefano Netti; Barbara Infante; Federica Spadaccino; Giulia Godeas; Maria Grazia Corallo; Concetta Prisciandaro; Laura Croce; Mario Rotondi; Loreto Gesualdo; Giovanni Stallone; Giuseppe Grandaliano; Elena Ranieri
Journal:  J Immunol Res       Date:  2019-11-05       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.